IDO1 and ovarian cancer: Although imatinib has shown minimal clinical benefit as a single agent in ovarian cancer (44, 45), it is well tolerated, and its ability to inhibit c-KIT and block IDO expression (35) suggests imatinib has potential to alleviate immune suppression as an adjuvant treatment for DC vaccination.